New York, New York--(Newsfile Corp. - December 31, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Reata Pharmaceuticals, Inc.("Reata" or the "Company") (NASDAQ: RETA). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.
The investigation concerns whether Reata and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On December 6, 2021, the U.S. Food and Drug Administration ("FDA") released a briefing document regarding Reata's chronic kidney disease drug candidate, bardoxolone methyl. Therein, the FDA stated that the data submitted by Reata did not "demonstrate that bardoxolone is effective in slowing the loss of kidney function in patients with [Alport syndrome]."
On this news, Reata's stock price fell $29.77 per share, or 37.8%, to close at $48.92 per share on December 6, 2021.
The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.
CONTACT:
Robert S. Willoughby
Pomerantz LLP
rswilloughby@pomlaw.com
888-476-6529 ext. 7980
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/108862
